Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy-Reference-Cited by-同舟云学术

Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy

Published:2022-01 Issue:1 Volume:1 Page:100004
ISSN:2772-9303
Container-title:Journal of the Society for Cardiovascular Angiography & Interventions
language:en
Short-container-title:Journal of the Society for Cardiovascular Angiography & Interventions

Author:

Patel Kush P.^ORCID,Lansky Alexandra J.,Kereiakes Dean J.^ORCID,Windecker Stephan,Cristea Ecaterina,Pietras Cody^ORCID,Dressler Ovidiu^ORCID,Issever M. Ozgu,Curtis Michael^ORCID,Bertolet Barry,Zidar James P.,Smits Pieter C.,Jiménez Díaz Victor Alfonso^ORCID,McLaurin Brent,Brogno David A.^ORCID,Janssens Luc,Vrolix Mathias C.,Gómez-Blázquez Iván^ORCID,Sahul Zakir H.,Kabour Ameer,Salido Luisa,Cleman Michael^ORCID,Saito Shigeru,Leon Martin B.,Baumbach Andreas^ORCID

Publisher

Elsevier BV

Reference26 articles.

1. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR);Sarno;Eur Heart J,2012

2. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials;Bangalore;Circulation,2012

3. Novel Supreme drug-eluting stents with early synchronized antiproliferative drug delivery to Inhibit smooth muscle cell proliferation after drug-eluting stents implantation in coronary artery disease: results of the PIONEER III randomized clinical trial;Lansky;Circulation,2021

4. Drug eluting stents for very long lesions: go long, but know the risks;Beale;Catheter Cardiovasc Interv,2017

5. Bioresorbable everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multicenter GHOST-EU registry;Geraci;JACC Cardiovasc Interv,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multi-center, randomized, double-blinded, parallel, placebo-controlled study to assess the efficacy and safety of Shenqisuxin granule in complex coronary artery disease after PCI: Study protocol;Frontiers in Cardiovascular Medicine;2022-09-12

2. A Warm Welcome to The First Issue of JSCAI;Journal of the Society for Cardiovascular Angiography & Interventions;2022-01